• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Bilibili Is Trading Lower By Over Around 14%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session

    9/8/22 12:15:08 PM ET
    $AEO
    $AGS
    $ALBO
    $ALLG
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary
    Miscellaneous manufacturing industries
    Consumer Discretionary
    Get the next $AEO alert in real time by email

    Gainers

    • ShiftPixy, Inc. (NASDAQ:PIXY) shares jumped 73.8% to $19.48 after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to shareholders.
    • Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) surged 64% to $29.35 after the FDA Advisory Committee voted that available evidence of effectiveness is sufficient to support approval of AMX0035 for the treatment of ALS. Citigroup and SVB Leerink raised their price targets.
    • Benitec Biopharma Inc. (NASDAQ:BNTC) shares rose 58% to $0.9346. The company, last week, filed its annual report on Form 10-K for the quarter ended June 30, 2022, with the U.S. Securities and Exchange Commission.
    • Rubius Therapeutics, Inc. (NASDAQ:RUBY) rose 39.4% to $1.21 after declining 11% on Wednesday. Rubius Therapeutics, last month, posted a Q2 loss of $0.49 per share.
    • Avenue Therapeutics, Inc. (NASDAQ:ATXI) gained 22.2% to $0.2733.
    • Nutex Health, Inc. (NASDAQ:NUTX) gained 21.5% to $3.85. Nutex Health recently posted a Q2 loss of $0.03 per share.
    • Asana, Inc. (NYSE:ASAN) shares gained 21% to $23.03 after the company reported better-than-expected results for its second quarter and issued a strong sales guidance. RBC Capital and Citigroup raised their price targets on the stock.
    • Relay Therapeutics, Inc. (NASDAQ:RLAY) surged 19.9% to $30.40. Relay Therapeutics announced efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients with a FGFR2-fusion or rearrangement FGFR inhibitor-naïve cholangiocarcinoma: ReFocus trial.
    • Allego N.V. (NYSE:ALLG) gained 17.6% to $4.63. Allego recently announced first half financial results and 2022 revenue expectations.
    • LifeStance Health Group, Inc. (NASDAQ:LFST) rose 17.6% to $8.95. LifeStance Health named Ken Burdick as CEO and Chairman.
    • Terns Pharmaceuticals, Inc. (NASDAQ:TERN) jumped 15.8% to $4.40.
    • AeroVironment, Inc. (NASDAQ:AVAV) gained 15.3% to $102.20 after reporting upbeat quarterly sales.
    • Eve Holding, Inc. (NYSE:EVEX) rose 14.8% to $7.07. United reported a $15 million investment in Eve Air Mobility and a conditional purchase agreement for 200 four-seat electric aircraft plus 200 options.
    • Cazoo Group Ltd (NYSE:CZOO) surged 14.7% to $0.70. The company announced it will wind down operations in mainland Europe to focus on core UK market
    • Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) rose 14.6% to $23.90. Rhythm Pharmaceuticals announced new employment inducement grants. Goldman Sachs maintained Rhythm Pharmaceuticals with a Buy and raised the price target from $28 to $31.
    • Forge Global Holdings, Inc. (NYSE:FRGE) rose 14.4% to $4.45.
    • Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) gained 14.1% to $680.56 after the company announced that the primary endpoints were met in two pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens in patients with diabetic macular edema and wet age-related macular degeneration.
    • Phreesia, Inc. (NYSE:PHR) rose 13.6% to $27.19 after the company reported better-than-expected Q2 sales results and raised the low-end of its FY23 sales guidance.
    • Intapp, Inc. (NASDAQ:INTA) gained 12.4% to $16.52 after the company reported better-than-expected Q4 results and issued guidance above estimates.
    • First High-School Education Group Co., Ltd. (NYSE:FHS) rose 11.4% to $0.7150.
    • Albireo Pharma, Inc. (NASDAQ:ALBO) surged 11% to $18.50. Guggenheim initiated coverage on Albireo Pharma with a Buy rating and announced a price target of $55.
    • Mullen Automotive, Inc. (NASDAQ:MULN) gained 10.7% to $0.7449 after the company announced it has acquired a 60% controlling interest in Bollinger Motors for $148.2 million in cash and stock.
    • Lyft, Inc. (NASDAQ:LYFT) gained 10.5% to $16.25 amid vague rumors from a questionable source mentioning the company.
    • Revance Therapeutics, Inc. (NASDAQ:RVNC) rose 9.4% to $22.78 after the company announced FDA approval of DAXXIFY for injection for temporary improvement of moderate to severe frown lines.
    • Snap Inc. (NYSE:SNAP) rose 7.3% to $12.29 on continued strength after a recent internal memo obtained by The Verge suggested the company is aiming to reach $6 billion in revenue and 450 million users by next year.
    • Heliogen, Inc. (NYSE:HLGN) rose 7% to $2.3650.
    • GameStop Corp. (NYSE:GME) rose 7% to $25.72 after the company reported better-than-expected earnings for its second quarter and also announced a partnership with cryptocurrency exchange FTX to bring more customers to the digital asset space.
    • Zillow Group, Inc. (NASDAQ:ZG) gained 6.9% to $37.80 after Jefferies maintained a Buy rating on the stock and raised its price target from $48 to $50.

     

    Losers

    • Great Panther Mining Limited (NYSE:GPL) shares dropped 21.4% to $0.2542. The company recently announced it has determined to file a notice of intention to make a proposal under the Bankruptcy and Insolvency Act, which will provide credit protection.
    • Troika Media Group, Inc. (NASDAQ:TRKA) fell 18.3% to $0.5310 after declining around 6% on Wednesday.
    • Erasca, Inc. (NASDAQ:ERAS) declined 18.1% to $7.70. Erasca announced preliminary Phase 1/1b monotherapy data for ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601 in BRAF-driven and RAS/MAPK-altered solid tumors.
    • PlayAGS, Inc. (NYSE:AGS) shares fell 17.4% to $6.29.
    • Biophytis S.A. (NASDAQ:BPTS) declined 16.2% to $0.9301. Biophytis recently announced top-line results from its phase 2-3 COVA clinical study evaluating Sarconeos in the treatment of COVID-19-related respiratory failure.
    • Ensysce Biosciences, Inc. (NASDAQ:ENSC) declined 15.8% to $0.3475.
    • Wheeler Real Estate Investment Trust, Inc. (NASDAQ:WHLR) dipped 15.2% to $1.68.
    • Bilibili Inc. (NASDAQ:BILI) fell 13.8% to $20.37 following Q2 results.
    • Tandy Leather Factory Inc. (NASDAQ:TLF) fell 13% to $5.35 following uplisting of its stock.
    • Graphex Group Limited (NASDAQ:GRFX) dropped 12.7% to $1.64. The company recently provided a business update and highlighted 2022 milestones.
    • MasterCraft Boat Holdings, Inc. (NASDAQ:MCFT) fell 12.3% to $20.84. The company posted upbeat quarterly earnings, but issued weak FY23 forecast. MasterCraft Boat also sold its NauticStar business to Iconic Marine Group.
    • Mercer International Inc. (NASDAQ:MERC) dipped 10.8% to $14.32.
    • Genenta Science S.p.A. (NASDAQ:GNTA) fell 10.7% to $4.75.
    • Chembio Diagnostics, Inc. (NASDAQ:CEMI) shares fell 10.6% to $0.56. Chembio Diagnostics filed for potential stock offering.
    • Dave & Buster's Entertainment, Inc. (NASDAQ:PLAY) dropped 10.2% to $39.47. While the company reported better-than-expected Q2 results, operating income dropped from 2021 levels.
    • Skillsoft Corp. (NYSE:SKIL) fell 10% to $2.42 after the company posted downbeat quarterly sales and authorized a $30 million share buyback.
    • The Lovesac Company (NASDAQ:LOVE) dropped 8.3% to $27.40 following Q2 results.
    • HyreCar Inc. (NASDAQ:HYRE) fell 8.2% to $1.2575. HyreCar shares gained around 8% on Wednesday after the company announced it has received a $100 million revolving line of credit from a premier global investment bank and Medalist Partners.
    • American Eagle Outfitters, Inc. (NYSE:AEO) shares fell 7.8% to $10.68 after the company reported worse-than-expected Q2 EPS results.
    • McCormick & Company, Incorporated (NYSE:MKC) fell 7.7% to $78.47. McCormick said it expects third-quarter FY22 sales to increase about 3% year-on-year and 6% in constant currency.
    • Grid Dynamics Holdings, Inc. (NASDAQ:GDYN) fell 7.5% to $18.31 after the company priced its common stock offering of about 5.71 million shares at $17.50 per share.
    • Wayfair Inc. (NYSE:W) fell 6.3% to $47.50 after the company reported a proposed offering of $600 million convertible senior notes.
    Get the next $AEO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AEO
    $AGS
    $ALBO
    $ALLG

    CompanyDatePrice TargetRatingAnalyst
    Wayfair Inc.
    $W
    2/20/2026$114.00 → $105.00Overweight
    Analyst
    Rhythm Pharmaceuticals Inc.
    $RYTM
    2/19/2026$478.00Outperform
    RBC Capital Mkts
    AeroVironment Inc.
    $AVAV
    2/18/2026$259.00Neutral
    UBS
    AeroVironment Inc.
    $AVAV
    2/17/2026$320.00Overweight
    Analyst
    Snap Inc.
    $SNAP
    2/10/2026$7.30Neutral → Buy
    Arete
    Terns Pharmaceuticals Inc.
    $TERN
    2/9/2026$58.00Outperform
    Leerink Partners
    Snap Inc.
    $SNAP
    2/6/2026$5.50Sell → Hold
    Stifel
    Snap Inc.
    $SNAP
    2/5/2026$10.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $AEO
    $AGS
    $ALBO
    $ALLG
    SEC Filings

    View All

    SEC Form 424B7 filed by LifeStance Health Group Inc.

    424B7 - LifeStance Health Group, Inc. (0001845257) (Filer)

    2/27/26 7:00:54 AM ET
    $LFST
    Medical/Nursing Services
    Health Care

    SEC Form S-3ASR filed by Rhythm Pharmaceuticals Inc.

    S-3ASR - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)

    2/26/26 5:37:52 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Rhythm Pharmaceuticals Inc.

    S-8 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)

    2/26/26 5:16:44 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEO
    $AGS
    $ALBO
    $ALLG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman, President & CEO Foley Brendan M acquired $4,481 worth of Common Stock - Voting (66 units at $67.90) and acquired $812 worth of Common Stock - Non Voting (12 units at $67.67), decreasing direct ownership by 99% to 1,383 units (SEC Form 4)

    4 - MCCORMICK & CO INC (0000063754) (Issuer)

    2/26/26 2:56:40 PM ET
    $MKC
    Packaged Foods
    Consumer Staples

    Chief Accounting Officer Morrow Rebecca was granted 66,033 shares, increasing direct ownership by 14% to 529,540 units (SEC Form 4)

    4 - Snap Inc (0001564408) (Issuer)

    2/25/26 7:00:02 PM ET
    $SNAP
    Computer Software: Programming Data Processing
    Technology

    Co-Founder Conine Steven sold $6,944,261 worth of shares (93,050 units at $74.63), decreasing direct ownership by 32% to 196,023 units (SEC Form 4)

    4 - Wayfair Inc. (0001616707) (Issuer)

    2/25/26 5:39:31 PM ET
    $W
    Catalog/Specialty Distribution
    Consumer Discretionary

    $AEO
    $AGS
    $ALBO
    $ALLG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Press Release: Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment

    Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged two to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is a chronic skin disease with underlying type 2 inflammation that can cause debilitating hives and recurring itch in young children Paris and Tarrytown, February 27, 2026. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of Dupixent (dupilumab) in the EU

    2/27/26 7:03:09 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment

    If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is a chronic skin disease with underlying type 2 inflammation that can cause debilitating hives and recurring itch in young children TARRYTOWN, N.Y. and PARIS, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of Dupixent® (dupilumab) in the European Union (EU) for the treatment of chronic spontane

    2/27/26 7:00:00 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genenta Advances Transformation into Saentra Forge, Strengthens ATC Governance and Expands Strategic Industrial Consolidation Platform

    MILAN, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ:GNTA) in transformation to Saentra Forge (NASDAQ:SAEN), a strategic industrial consolidator focused on biotech, defense, aerospace, and national-security-related technologies, today announced the appointment of Paolo Salvato to the Board of Directors of ATC, a manufacturer of tactical defense systems representing the Company's initial entry into defense technology manufacturing. The Company also provided an update on its ongoing evaluation of majority-control acquisition opportunities in regulated national-security sectors. Mr. Salvato previously served as Chief Executive Officer of Fiocchi Munizioni S.p.A. (CSG Group

    2/27/26 4:00:00 AM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AEO
    $AGS
    $ALBO
    $ALLG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Analyst reiterated coverage on Wayfair with a new price target

    Analyst reiterated coverage of Wayfair with a rating of Overweight and set a new price target of $105.00 from $114.00 previously

    2/20/26 10:42:01 AM ET
    $W
    Catalog/Specialty Distribution
    Consumer Discretionary

    RBC Capital Mkts initiated coverage on Rhythm Pharmaceuticals with a new price target

    RBC Capital Mkts initiated coverage of Rhythm Pharmaceuticals with a rating of Outperform and set a new price target of $478.00

    2/19/26 7:52:12 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UBS initiated coverage on AeroVironment with a new price target

    UBS initiated coverage of AeroVironment with a rating of Neutral and set a new price target of $259.00

    2/18/26 7:53:34 AM ET
    $AVAV
    Aerospace
    Industrials

    $AEO
    $AGS
    $ALBO
    $ALLG
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 7, 2024 - FDA Roundup: June 7, 2024

    For Immediate Release: June 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced that it has advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in the United States should be monovalent (single strain) JN.1 vaccines to more closely match cu

    6/7/24 3:46:22 PM ET
    $GERN
    $SRAX
    $SNAP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Advertising
    Consumer Discretionary

    March 22, 2024 - FDA Roundup: March 22, 2024

    For Immediate Release: March 22, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued an emergency use authorization for Pemgarda (pemivibart) for the pre-exposure prophylaxis (prevention) of COVID-19 in certain adults and adolescents (12 years of age and older weighing at least 40 kilograms [about 88 pounds]).  Pemgarda is

    3/22/24 5:02:42 PM ET
    $SNAP
    $SRAX
    Computer Software: Programming Data Processing
    Technology
    Advertising
    Consumer Discretionary

    November 9, 2023 - FDA Approves First Treatment for Patients with Rare Inherited Blood Clotting Disorder

    For Immediate Release: November 09, 2023 Today, the U.S. Food and Drug Administration approved Adzynma, the first recombinant (genetically engineered) protein product indicated for prophylactic (preventive) or on demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP), a rare and life-threatening blood clotting disorder. “The FDA remains

    11/9/23 2:30:20 PM ET
    $SRAX
    $SNAP
    Advertising
    Consumer Discretionary
    Computer Software: Programming Data Processing
    Technology

    $AEO
    $AGS
    $ALBO
    $ALLG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Risher John David bought $100,179 worth of shares (7,490 units at $13.38), increasing direct ownership by 0.07% to 11,481,792 units (SEC Form 4)

    4 - Lyft, Inc. (0001759509) (Issuer)

    2/18/26 4:10:21 PM ET
    $LYFT
    Real Estate

    Director Cheng Lawrence bought $114,368 worth of shares (5,000 units at $22.87) (SEC Form 4)

    4 - GameStop Corp. (0001326380) (Issuer)

    1/26/26 9:06:47 AM ET
    $GME
    Electronics Distribution
    Consumer Discretionary

    President, CEO and Chairman Cohen Ryan bought $21,359,200 worth of shares (1,000,000 units at $21.36), increasing direct ownership by 3% to 38,347,842 units (SEC Form 4)

    4 - GameStop Corp. (0001326380) (Issuer)

    1/22/26 4:02:03 PM ET
    $GME
    Electronics Distribution
    Consumer Discretionary

    $AEO
    $AGS
    $ALBO
    $ALLG
    Financials

    Live finance-specific insights

    View All

    Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update

    -- Fourth quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $57.3 million -- -- March 20, 2026 PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic obesity (HO) ---- Phase 2 open-label extension data showed bivamelagon achieved persistent BMI reductions at six and nine months; Completed positive end-of-Phase-2 meeting with FDA ---- On track to report topline data from 12-patient Japanese cohort of setmelanotide Phase 3 trial in acquired HO in March 2026 -- -- On track to report topline data from Phase 3 EMANATE trial evaluating setmelanotide in rare genetically caused melanocortin-4 receptor (MC4R) pathway diseases in March 2026 -- -- Manag

    2/26/26 7:00:00 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nutex Health Schedules 2025 Fourth Quarter and Year-End Financial Results and Earnings Conference Call

    HOUSTON, Feb. 25, 2026 /PRNewswire/ -- Nutex Health, Inc. (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 27 state-of-the-art micro hospitals and hospital outpatient departments in 12 states and primary care-centric, risk-bearing physician networks, today announced that it plans to file its Annual Report on Form 10‑K for the fiscal year ended December 31, 2025, on Thursday, March 5, 2026, after the market close. The Company will also issue a corresponding press release summarizing financial results on the same day. Nutex Health will host its earnings conference call on Friday, March 6, 2026, at 9:30 a.m. CT to discuss the Company's financial performance and

    2/25/26 5:29:00 PM ET
    $NUTX
    Real Estate

    Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

    Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") will report its fourth quarter and full year 2025 financial results on Tuesday, March 3, 2026. Amylyx's senior management team will host a conference call and audio webcast at 8:00 a.m. ET to discuss the financial results and other company updates. To access the conference call, please dial +1 (888) 880-3330 (U.S. & Canada) or +1 (646) 357-8766 (international) at least 10 minutes prior to the start time and ask to be joined into the Amylyx Pharmaceuticals call. A live audio webcast of the call will be available under "Events and Presentations" in the Investor section of the Company's website, https://investors.amylyx.c

    2/24/26 9:00:00 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEO
    $AGS
    $ALBO
    $ALLG
    Leadership Updates

    Live Leadership Updates

    View All

    Genenta Advances Transformation into Saentra Forge, Strengthens ATC Governance and Expands Strategic Industrial Consolidation Platform

    MILAN, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ:GNTA) in transformation to Saentra Forge (NASDAQ:SAEN), a strategic industrial consolidator focused on biotech, defense, aerospace, and national-security-related technologies, today announced the appointment of Paolo Salvato to the Board of Directors of ATC, a manufacturer of tactical defense systems representing the Company's initial entry into defense technology manufacturing. The Company also provided an update on its ongoing evaluation of majority-control acquisition opportunities in regulated national-security sectors. Mr. Salvato previously served as Chief Executive Officer of Fiocchi Munizioni S.p.A. (CSG Group

    2/27/26 4:00:00 AM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AV Announces Retirement of Chief Financial Officer Kevin McDonnell

    AeroVironment, Inc. ("AV" or the "Company") (NASDAQ:AVAV), a global defense technology leader, today announced that Kevin McDonnell, Executive Vice President and Chief Financial Officer, has informed the Company of his decision to retire from AV, effective July 31, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223105811/en/McDonnell joined AV in 2020. During his tenure as CFO, AV strengthened its balance sheet, enhanced its financial and operational discipline, completed strategic acquisitions and organic growth initiatives, and reinforced its capital allocation framework to drive long-term shareholder value. "Kevin ha

    2/23/26 5:13:00 PM ET
    $AVAV
    Aerospace
    Industrials

    Sunbit Appoints Shachar G. Scott as Chief Marketing Officer to Accelerate its Next Phase of Growth

    Veteran global marketing leader joins from Meta as Sunbit scales products, partnerships and infrastructure to serve millions more consumers Sunbit, the personalized financial partner for everyday life, today announced the appointment of Shachar G. Scott as Chief Marketing Officer, signaling a pivotal next chapter in the company's growth. Scott brings more than 25 years of experience building and scaling global brands across technology and consumer products with leadership roles at Meta (NASDAQ:META), Apple (NASDAQ:AAPL), Bumble (NASDAQ:BMBL) and Snap (NYSE:SNAP). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260212757677/en/S

    2/12/26 10:14:00 AM ET
    $AAPL
    $BMBL
    $META
    Computer Manufacturing
    Technology
    Computer Software: Programming Data Processing

    $AEO
    $AGS
    $ALBO
    $ALLG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Wheeler Real Estate Investment Trust Inc.

    SC 13D/A - Wheeler Real Estate Investment Trust, Inc. (0001527541) (Subject)

    12/9/24 5:54:19 PM ET
    $WHLR
    Real Estate Investment Trusts
    Real Estate

    Amendment: SEC Form SC 13G/A filed by Benitec Biopharma Inc.

    SC 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)

    12/6/24 1:47:28 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Wheeler Real Estate Investment Trust Inc.

    SC 13G/A - Wheeler Real Estate Investment Trust, Inc. (0001527541) (Subject)

    12/5/24 5:28:41 PM ET
    $WHLR
    Real Estate Investment Trusts
    Real Estate